Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Jia Jie Biomedical Co., Ltd. specializes in the production of packaged food products, particularly focusing on health-oriented offerings such as functional snacks and dietary supplements. The company operates primarily in Taiwan and has a competitive edge through its innovative product formulations and strong brand recognition in the local market.
Jia Jie Biomedical generates revenue through the sale of health-focused packaged foods, leveraging its strong brand loyalty and innovative product development to command premium pricing. The company benefits from low debt levels (Debt/Equity of 0.05), allowing for flexibility in pricing strategies and investment in new product lines.
Changes in consumer health trends impacting demand for functional foods
Regulatory changes affecting food safety and labeling requirements
Fluctuations in raw material costs, particularly for health ingredients
Market expansion efforts into Southeast Asia
Increased competition from larger food manufacturers entering the health food space
Potential regulatory changes impacting product formulations and marketing
Aggressive pricing strategies from competitors
Emerging local brands with innovative products gaining market share
Low operating cash flow could limit operational flexibility
Negative free cash flow may restrict future investments
moderate - The company’s performance is somewhat linked to consumer spending patterns, particularly in discretionary health food segments.
Minimal impact as the company has low debt levels; however, rising interest rates could indirectly affect consumer spending on premium products.
minimal - The company operates with low leverage, reducing sensitivity to credit market fluctuations.
value - Investors may find the low Price/Book ratio (0.9x) appealing despite recent performance challenges.
moderate - The stock has shown significant price fluctuations, evidenced by a 1-Year Return of -25.6%.